How do you pay?
Which strength? Pick yours
How many tablets?

How to pay the least

From

$26.97 for 30 tablets

Generic cefpodoxime proxetil with the free Team Cuban Card, at pharmacies that take it. Pick the strength on your label for its own price.

What to do

  1. Get the free Team Cuban Card. It costs nothing to sign up.See the price and get the card 
  2. At a pharmacy that takes it, show the card and ask for generic cefpodoxime proxetil.Find a pharmacy that takes it 

Other ways

By mail, if you can wait a few days From $22.33 for 30 tablets delivered ($17.08 plus $5.25 shipping) from Cost Plus Drugs. Make a free account, then have your prescription sent there.

Open Cost Plus Drugs 

Every company’s cefpodoxime proxetil is rated by the FDA to work the same, so any pharmacy can fill your prescription with the one it stocks.

See every pharmacy’s price

Where to buy it

Pharmacies’ own cash prices for generic cefpodoxime proxetil, lowest first.

Pick up in storeDelivered

From each pharmacy’s own site, read November 17, 2026. Confirm the price before you fill.

About these prices

Prices change, can differ by store and state, and may depend on the strength and how many you take. With insurance, ask what your plan charges; it can be less.

Who makes it

5 companies sell cefpodoxime proxetil in this form, each one rated by the FDA as a substitute for the others. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.

  • Amici Pharma100 mg, 200 mg

    Has lactose · Has dyes: FD&C Yellow No. 5, FD&C Yellow No. 6 · Made by Alkem Laboratories

    How it looks, what’s in it, NDCs

    100 mg Orange, oval, 12 mm, marked “A55”

    PackageNDC
    Bottle of 10069292-514-01
    Bottle of 50069292-514-50

    200 mg Orange, capsule, 16 mm, marked “A57”

    PackageNDC
    Bottle of 10069292-516-01
    Bottle of 50069292-516-50

    Inactive ingredients: carboxymethylcellulose calcium, silicon dioxide, crospovidone, FD&C Yellow No. 5, FD&C Yellow No. 6, hydroxypropyl cellulose, hypromelloses, ferric oxide red, lactose monohydrate, polyethylene glycol, magnesium stearate, sodium lauryl sulfate, titanium dioxide

    FDA label

  • Ascend Laboratories100 mg, 200 mg

    Has lactose · Has a dye: FD&C Yellow No. 6 · Made by Alkem Laboratories

    How it looks, what’s in it, NDCs

    100 mg Orange, oval, 12 mm, marked “A55”

    PackageNDC
    Bottle of 2067877-878-20
    Bottle of 10067877-878-01
    Bottle of 50067877-878-05

    200 mg Orange, capsule, 16 mm, marked “A57”

    PackageNDC
    Bottle of 2067877-879-20
    Bottle of 10067877-879-01
    Bottle of 50067877-879-05

    Inactive ingredients: carboxymethylcellulose calcium, silicon dioxide, crospovidone, FD&C Yellow No. 6, hydroxypropyl cellulose, hypromelloses, ferric oxide red, lactose monohydrate, polyethylene glycol, magnesium stearate, sodium lauryl sulfate, titanium dioxide

    FDA label

  • Aurobindo Pharma100 mg, 200 mg

    Has lactose · Has dyes: FD&C Yellow No. 6, FD&C Red No. 40

    Product page on aurobindousa.com

    How it looks, what’s in it, NDCs

    100 mg Light Yellowish-Orange, oval, 11 mm, marked “C / 61”

    PackageNDC
    Bottle of 2065862-095-20
    Bottle of 10065862-095-01
    Bottle of 25065862-095-25
    Bottle of 100065862-095-99

    200 mg Coral Red, oval, 15 mm, marked “C / 62”

    PackageNDC
    Bottle of 2065862-096-20
    Bottle of 10065862-096-01
    Bottle of 25065862-096-25
    Bottle of 100065862-096-99

    Inactive ingredients: carboxymethylcellulose calcium, lactose monohydrate, hydroxypropyl cellulose (1600000 wamw), sodium lauryl sulfate, crospovidone (120 .mu.m), starch, corn, magnesium stearate, hypromellose 2910 (6 mpa.s), titanium dioxide, propylene glycol, FD&C Yellow No. 6, ferric oxide yellow, FD&C Red No. 40

    FDA label

  • NorthStar Rx100 mg, 200 mg

    Has lactose · Has dyes: FD&C Yellow No. 6, FD&C Red No. 40 · Made by Aurobindo Pharma

    Product page on northstarrxllc.com

    How it looks, what’s in it, NDCs

    100 mg Light Yellowish-Orange, oval, 11 mm, marked “C / 61”

    PackageNDC
    Bottle of 2016714-394-01

    200 mg Coral Red, oval, 15 mm, marked “C / 62”

    PackageNDC
    Bottle of 2016714-395-01

    Inactive ingredients: carboxymethylcellulose calcium, lactose monohydrate, hydroxypropyl cellulose (1600000 wamw), sodium lauryl sulfate, crospovidone (15 mpa.s at 5%), starch, corn, magnesium stearate, hypromellose 2910 (6 mpa.s), titanium dioxide, propylene glycol, FD&C Yellow No. 6, ferric oxide yellow, FD&C Red No. 40

    FDA label

  • Sandoz100 mg, 200 mg

    Has lactose · Has a dye: FD&C Yellow No. 6

    How it looks, what’s in it, NDCs

    100 mg Light orange, oval, 16 mm, marked “SZ / 438”

    PackageNDC
    Bottle of 200781-5438-20
    Bottle of 1000781-5438-01

    200 mg Light orange, oval, 16 mm, marked “SZ / 439”

    PackageNDC
    Bottle of 200781-5439-20
    Bottle of 1000781-5439-01

    Inactive ingredients: carboxymethylcellulose calcium, crospovidone (15 mpa.s at 5%), FD&C Yellow No. 6, hydroxypropyl cellulose (1600000 wamw), hypromellose, lactose monohydrate, magnesium stearate, sodium lauryl sulfate, talc, titanium dioxide

    FDA label

Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.

What to say at the pharmacy

“Before you fill it, what would I pay for generic cefpodoxime proxetil?”

Paying cash? Ask for the cash price. With insurance, ask what your plan charges.

What it’s used for

What the FDA label says

Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N. gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes. Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications. (See DOSAGE AND ADMINISTRATION.) Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis. Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Staphylococcus saprophyticus. NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents. (See CLINICAL STUDIES section.) Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil and other antibacterial drugs, cefpodoxime proxetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Source: the FDA label for Cefpodoxime (NorthStar Rx LLC), January 3, 2024. Full label on DailyMed 

Good to know

  • Different companies’ cefpodoxime proxetil can look different. The FDA requires each to work the same way.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.